World Alzheimer’s Day: Sant Pau Focuses on Individuals with Down Syndrome

On World Alzheimer’s Day, the aim is to raise awareness about this incurable neurodegenerative disease that primarily affects elderly individuals. However, this year, Hospital de Sant Pau has shifted its attention to a particularly vulnerable group: individuals with Down syndrome. Alzheimer’s is characterized by cognitive decline and behavioral disturbances, with recent memory loss being one … Read more

Cross-sectional versus longitudinal cognitive assessments for the diagnosis of symptomatic Alzheimer’s disease in adults with Down syndrome

Cross-sectional versus longitudinal cognitive assessments for the diagnosis of symptomatic Alzheimer's disease in adults with Down syndrome

Cross-sectional versus longitudinal cognitive assessments for the diagnosis of symptomatic Alzheimer’s disease in adults with Down syndrome Individuals with Down syndrome are at a high risk of developing the clinical symptoms of Alzheimer’s disease in old age due to the triplicating of chromosome 21. However, the clinical diagnosis of this disease is challenging, mainly due … Read more

GFAP in plasma and CSF in Down syndrome and Alzheimer’s disease

gfap - Sant Pau Memory Unit - Montoliu-Gaia - Alcolea

Alzheimer’s Disease, Down Syndrome and GFAP People with Down syndrome are at higher risk of developing Alzheimer’s disease than the general population. In fact, by the age of 70, more than 95% of people with Down syndrome will develop Alzheimer’s disease, which is the leading cause of death in this population. This strong association is … Read more

The Trial Ready Cohort-Down Syndrome (TRC-DS) begins

TRC-DS

A pioneering international study that accelerates the inclusion of adults with Down Syndrome in clinical trials is starting at the Alzheimer-Down Unit of the Hospital de Sant Pau and the Fundació Catalana de Síndome de Down in Barcelona. The Trial Ready Cohort-Down Syndrome (TRC-DS), a new international study funded by the US National Institutes of … Read more

New plasma biomarker to detect Alzheimer’s disease in Down syndrome individuals

Down Alzheimer - Plasma Markers - APOE

Plasma biomarkers Scientists worldwide are immersed in the race for accurate, non-invasive and accessible biomarkers to detect and diagnose Alzheimer’s Disease. To date, major scientific advances allowed the identification of several biomarkers in cerebrospinal fluid or using positron emission tomography (PET). Yet, these methods are either invasive or expensive and not easily accessible to all … Read more